menu
    • menu
    [{"orgOrder":0,"company":"LG Chem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"LC51-0255","moa":"S1P1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"LG Chem \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ Not Applicable"},{"orgOrder":0,"company":"LG Chem","sponsor":"TransThera Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"TT-01025","moa":"VAP-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"LG Chem","amount2":0.34999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0.34999999999999998,"dosageForm":"Oral","sponsorNew":"LG Chem \/ LG Chem Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"LG Chem \/ LG Chem Life Sciences"},{"orgOrder":0,"company":"LG Chem","sponsor":"Avacta Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"AVA6000","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"LG Chem","amount2":0.45000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"LG Chem \/ LG Chem Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"LG Chem \/ LG Chem Life Sciences"},{"orgOrder":0,"company":"LG Chem","sponsor":"Avacta Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2021","type":"Partnership","leadProduct":"PD-L1 XT","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"LG Chem","amount2":0.45000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"LG Chem \/ LG Chem Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"LG Chem \/ LG Chem Life Sciences"},{"orgOrder":0,"company":"LG Chem","sponsor":"Avacta Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Expanded Collaboration","leadProduct":"PD-L1 XT","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"LG Chem \/ LG Chem","highestDevelopmentStatusID":"4","companyTruncated":"LG Chem \/ LG Chem"},{"orgOrder":0,"company":"LG Chem","sponsor":"MaxCyte","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"LR19023","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"LG Chem \/ LG Chem","highestDevelopmentStatusID":"4","companyTruncated":"LG Chem \/ LG Chem"},{"orgOrder":0,"company":"LG Chem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"LG203003","moa":"DGAT2","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"LG Chem \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"LG Chem \/ Not Applicable"},{"orgOrder":0,"company":"LG Chem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"SOUTH KOREA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tigulixostat","moa":"Xanthine oxidase","graph1":"Rheumatology","graph2":"Phase III","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LG Chem \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"LG Chem \/ Not Applicable"},{"orgOrder":0,"company":"LG Chem","sponsor":"Aveo Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Tivozanib","moa":"VEGFR 1","graph1":"Oncology","graph2":"Approved","graph3":"LG Chem","amount2":0.56999999999999995,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.56999999999999995,"dosageForm":"Capsule","sponsorNew":"LG Chem \/ LG Chem","highestDevelopmentStatusID":"12","companyTruncated":"LG Chem \/ LG Chem"},{"orgOrder":0,"company":"LG Chem","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"SOUTH KOREA","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Tigulixostat","moa":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"LG Chem","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"LG Chem \/ Innovent Biologics","highestDevelopmentStatusID":"10","companyTruncated":"LG Chem \/ Innovent Biologics"},{"orgOrder":0,"company":"LG Chem","sponsor":"UNICEF","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Sabin Inactivated Polio Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"LG Chem","amount2":0.20000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.20000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"LG Chem \/ UNICEF","highestDevelopmentStatusID":"12","companyTruncated":"LG Chem \/ UNICEF"},{"orgOrder":0,"company":"LG Chem","sponsor":"Rhythm Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"LB54640","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"LG Chem","amount2":0.31,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.31,"dosageForm":"","sponsorNew":"LG Chem \/ Rhythm Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ Rhythm Pharmaceuticals"},{"orgOrder":0,"company":"LG Chem","sponsor":"Aveo Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"LB-LR1109","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"LG Chem \/ AVEO Oncology","highestDevelopmentStatusID":"6","companyTruncated":"LG Chem \/ AVEO Oncology"},{"orgOrder":0,"company":"LG Chem","sponsor":"Yifan Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","graph1":"Technology","graph2":"Approved","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"LG Chem \/ Yifan Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"LG Chem \/ Yifan Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by LG Chem

    Menu

    LG Chem

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            LG Chem

                            South Korea arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            LG Chem

                            South Korea arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hyaluronic Acid

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved

                            Sponsor : Yifan Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LG Chem enters Chinese osteoarthritis treatment market

                            Details : Hyruan One (hyaluronic acid) is a small molecule, dihydrofolate reductase inhibitor, given intra-articularly. It is China’s first single-injection osteoarthritis treatment.

                            Brand Name : Hyruan One

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 03, 2024

                            Lead Product(s) : Hyaluronic Acid

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved

                            Sponsor : Yifan Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            LG Chem

                            South Korea arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            LG Chem

                            South Korea arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LB-LR1109

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Aveo Oncology

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LG Chem and AVEO Start Phase 1 Anti-Cancer Compound Study

                            Details : LB-LR1109, an anti-cancer investigational drug, works by modulationg LILRB1, it is being investigated in unresectable and metastatic non-small cell lung cancer, renal cell carcinoma, etc.

                            Brand Name : LB-LR1109

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 13, 2024

                            Lead Product(s) : LB-LR1109

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Aveo Oncology

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            LG Chem

                            South Korea arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            LG Chem

                            South Korea arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LB54640

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Rhythm Pharmaceuticals

                            Deal Size : $305.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Rhythm Acquires Global Rights To Oral MC4R Agonist LB54640

                            Details : Under the agreement, Rhythm will acquire global rights for LB54640, an investigational oral small molecule MC4R agonist now in Phase 2 trials for patients with acquired hypothalamic obesity.

                            Brand Name : LB54640

                            Molecule Type : Small molecule

                            Upfront Cash : $100.0 million

                            January 04, 2024

                            Lead Product(s) : LB54640

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Rhythm Pharmaceuticals

                            Deal Size : $305.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            LG Chem

                            South Korea arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            LG Chem

                            South Korea arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sabin Inactivated Polio Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : UNICEF

                            Deal Size : $200.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            LG Chem to Supply UNICEF with $200 Million Worth of Essential Vaccines

                            Details : Under the terms of the agreement, LG Chem will supply UNICEF with its polio vaccine Eupolio and a pentavalent vaccine Eupenta that prevents diphtheria, pertussis, tetanus, hepatitis B and meningitis to solve global public health issues.

                            Brand Name : Eupolio

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 14, 2023

                            Lead Product(s) : Sabin Inactivated Polio Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : UNICEF

                            Deal Size : $200.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            LG Chem

                            South Korea arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            LG Chem

                            South Korea arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tigulixostat

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase III

                            Sponsor : Innovent Biologics

                            Deal Size : $95.5 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Innovent and LG Chem Announce Strategic Collaboration for Tigulixostat, a Novel Non-Purine Xanthine Oxidase In...

                            Details : LC350189 (tigulixostat) is a novel xanthine oxidase inhibitor targeting the reduction of uric acid in purine metabolism, by inhibiting the activity of xanthine oxidase.

                            Brand Name : LC350189

                            Molecule Type : Small molecule

                            Upfront Cash : $10.0 million

                            December 14, 2022

                            Lead Product(s) : Tigulixostat

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase III

                            Sponsor : Innovent Biologics

                            Deal Size : $95.5 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            LG Chem

                            South Korea arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            LG Chem

                            South Korea arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tivozanib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : Aveo Oncology

                            Deal Size : $566.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash

                            Details : AVEO will establish LG Chem’s commercial presence in oncology through AVEO’s lead product, FOTIVDA® (tivozanib), which received U.S. FDA approval for the treatment of relapsed or refractory advanced renal cell carcinoma following two or more prior s...

                            Brand Name : Fotivda

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 18, 2022

                            Lead Product(s) : Tivozanib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : Aveo Oncology

                            Deal Size : $566.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            LG Chem

                            South Korea arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            LG Chem

                            South Korea arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tigulixostat

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LG Chem Enters Final Stage of Clinical Development for New Gout Drug

                            Details : Results from US Phase 2 clinical trial—primary end point set at a challenging level confirmed the potential of LC350189 (tigulixostat) as a new gout treatment distinguished from pre-existing drugs, while also demonstrating safety similar to that of the...

                            Brand Name : LC350189

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 03, 2022

                            Lead Product(s) : Tigulixostat

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            LG Chem

                            South Korea arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            LG Chem

                            South Korea arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LG203003

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LG Chem Announces First Subject Enrolled in Phase 1 Clinical Trial of NASH New Drug

                            Details : LG203003 is second NASH compound is formulated to suppress the accumulation of fat in liver cells by selectively impeding the activation of DGAT2 (diacylglycerol O-acyltransferase 2), a triglyceride synthetase, thus reducing liver cell damage.

                            Brand Name : LG203003

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 14, 2022

                            Lead Product(s) : LG203003

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            LG Chem

                            South Korea arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            LG Chem

                            South Korea arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LR19023

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : MaxCyte

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs

                            Details : LG Chem is strengthening its anti-cancer sector through advanced construction of cell drug platform technologies. LR19023, the next-generation CAR-T cell treatment, is currently in the pre-clinical stage and under development as a solid cancer therapeuti...

                            Brand Name : LR19023

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            July 12, 2022

                            Lead Product(s) : LR19023

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : MaxCyte

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            LG Chem

                            South Korea arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            LG Chem

                            South Korea arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PD-L1 XT

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Avacta Group

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            LG Chem Renews License Triggering Payment to Avacta

                            Details : Under the terms of the agreement, LG Chem has the exclusive rights to develop and commercialise, on a global basis, Avacta’s Affimer® PD-L1 inhibitor (PD-L1 XT) with Affimer XT™ serum half-life extension for a range of indications.

                            Brand Name : PD-L1 XT

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 30, 2022

                            Lead Product(s) : PD-L1 XT

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Avacta Group

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth